hackint0sh/New-Dataset huggingface dataset:
The experimentation is conducted to answer this question: "Can betamethasone help reduce fever more quickly in a child with viral adenovirus infection? "The secondary objective is to assess if the child's overall clinical conditions improve more rapidly (reduced sore throat, quicker return to regular eating) and a reduction in the incidence and duration of hospitalizations. conditions: Adenovirus studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: A double-blind, placebo-controlled randomized study primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: The nurse that will prepare and administer the treatment to the patient won't be masked whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: Bentelan name: Placebo measure: Proportion of patients with a sustained fever resolution at 24 hours from randomization measure: Pharyngeal-tonsillar pain level in patients younger than 36 months measure: Hospitalization measure: Duration of hospitalization (among those hospitalized), measured in days measure: Cumulative incidence of fever resolution measure: Fever duration measure: Pharyngeal-tonsillar pain level in patients older than 36 months sex: ALL minimumAge: 6 Months maximumAge: 6 Years stdAges: CHILD facility: Ospedale Infantile Regina Margherita status: RECRUITING city: Torino zip: 10126 country: Italy name: Virginia Giannone, MD role: CONTACT phone: +390113135063 email: vgiannone@cittadellasalute.to.it name: Marco Denina, MD role: CONTACT phone: +390113135064 email: mdenina@cittadellasalute.to.it name: Emanuele castagno, MD role: SUB_INVESTIGATOR name: Giannone Virginia, MD role: SUB_INVESTIGATOR name: Marco Denina, MD role: SUB_INVESTIGATOR lat: 45.07049 lon: 7.68682 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2023-06-12 uploadDate: 2023-12-06T05:08 filename: Prot_SAP_000.pdf size: 963093 hasResults: False
nctId: NCT06299800 id: CE385/2023 briefTitle: Phenotyping Patients With Type 2 Diabetes Mellitus and Cancer acronym: TCPT2023 overallStatus: RECRUITING date: 2024-02-04 date: 2025-02-04 date: 2025-02-04 date: 2024-03-08 date: 2024-03-08 name: Azienda Ospedaliero Universitaria Maggiore della Carita class: OTHER briefSummary: Recent research has highlighted the significant relationship between type 2 diabetes mellitus and cancer, both prevalent and impactful on global health. The intrinsic correlation arises from shared metabolic processes, particularly a systemic and chronic inflammatory state driven by factors like obesity, dyslipidemia, and hyperglycemia. This leads to the creation of a self-sustaining microenvironment known as meta-inflammation, promoting cancer development through DNA damage, oxidative stress, and the influence of hormones like leptin. The hyperglycemic environment in diabetes contributes to cancer development, supporting the Warburg effect and insulin-related mechanisms. This study aims to identify risk factors associated with diabetes that impact tumor development and progression, crucial for guiding effective preventive strategies in clinical practice.
* assess the relationship between the characteristics of patients and the time to the onset of cancer. conditions: Diabetes Mellitus, Type 2 conditions: Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 779 type: ESTIMATED name: phenotyping of patients followed at a third-level diabetes centre with cancer measure: Smoking assessment at first visit measure: Alcool consumption at first visit measure: BMI assessment at first visit measure: Glycated assessment at first visit measure: First-line therapy characteristics assessment at first visit measure: Primary outcomes and recurrence or presence of a secondary tumor measure: Relationship between patients characteristics and the time onset of cancer considering anthropometric and biochemical data measure: Tumour characterization in the considered population, detected at the first clinical visit sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: SCDU Endocrinology, AOU Ospedale Maggiore della Carità status: RECRUITING city: Novara zip: 28100 country: Italy name: Flavia Prodam role: CONTACT phone: +39 0321 660 693 email: flavia.prodam@med.uniupo.it lat: 45.44694 lon: 8.62118 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2023-09-10 uploadDate: 2024-03-01T05:46 filename: Prot_SAP_000.pdf size: 525402 hasResults: False
nctId: NCT06299787 id: 058-2021 briefTitle: Cognitive Dysfunction in the Addictions Study - Project 4 (P4) acronym: CDiA-P4 overallStatus: RECRUITING date: 2022-02-07 date: 2024-12-31 date: 2025-07-01 date: 2024-03-08 date: 2024-03-08 name: Centre for Addiction and Mental Health class: OTHER briefSummary: The prefrontal cortex, although well established as an efficacious target for the treatment of major depressive disorder (MDD), has recently come into favour as a therapeutic target for alcohol use disorders (AUD). Depressive symptoms are also highly prevalent in individuals with AUD. A number of cognitive and psychological processes stemming from the prefrontal cortex, a common treatment target for repetitive transcranial magnetic stimulation (rTMS), are disrupted in both MDD and AUD. The proposed study will enhance the development of theta burst stimulation (TBS) as a new intervention for AUD in the context of depressive symptoms and uses integrated TMS-EEG to identify neurophysiological targets of executive dysfunction in this disorder. conditions: Major Depressive Disorder conditions: Alcohol Use Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 40 type: ESTIMATED name: intermittent theta burst stimulation name: Sham stimulation measure: Executive Function Index - inhibition measure: Executive Function Index - working memory measure: Executive Function Index - set shifting measure: 17-Item Hamilton Depression Rating Scale (HRSD-17) measure: Columbia-Suicide Severity Rating Scale sex: ALL minimumAge: 18 Years maximumAge: 59 Years stdAges: ADULT facility: Centre for Addiction and Mental Health status: RECRUITING city: Toronto state: Ontario zip: M6J 1H4 country: Canada name: Daphne Voineskos, MD role: CONTACT phone: 416-535-8501 phoneExt: 30176 email: daphne.voineskos@camh.ca lat: 43.70011 lon: -79.4163 hasResults: False
nctId: NCT06299774 id: 2023P003383 briefTitle: Emergency Care at Home overallStatus: RECRUITING date: 2024-02-02 date: 2025-02-02 date: 2025-03-02 date: 2024-03-08 date: 2024-03-08 name: Brigham and Women's Hospital class: OTHER briefSummary: This study will assess the efficacy of receiving emergency care at home versus in the brick-and-mortar emergency department. conditions: Emergency Medical Services conditions: Emergency Department Visits studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 1500 type: ESTIMATED name: Emergency care at home name: Emergency care at a brick-and-mortar emergency department measure: Participant with an emergency department presentation, observation, or hospitalization within 9 days measure: Time to care initiation measure: Time spent receiving care measure: Number of days at home within 9 days sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Massachusetts General Hospital status: RECRUITING city: Boston state: Massachusetts zip: 02114 country: United States name: David Levine, MD, MPH, MA role: CONTACT phone: 617-732-7063 email: dmlevine@bwh.harvard.edu lat: 42.35843 lon: -71.05977 hasResults: False
nctId: NCT06299761 id: BBI-825-101 briefTitle: Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications acronym: STARMAP overallStatus: RECRUITING date: 2024-03-28 date: 2027-02 date: 2027-02 date: 2024-03-08 date: 2024-04-29 name: Boundless Bio class: INDUSTRY briefSummary: BBI-825 is a potent, selective, oral, small molecule inhibitor of ribonucleotide reductase (RNR). This is a first-in-human, open-label, non-randomized, 3-part, Phase 1/2 study to determine the safety profile and identify the maximum tolerated dose and recommended Phase 2 dose of BBI-825 administered as a single agent and in combination with select targeted therapies. conditions: Solid Tumor studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SEQUENTIAL interventionModelDescription: BBI-825 single agent dose escalation primaryPurpose: TREATMENT masking: NONE count: 42 type: ESTIMATED name: BBI-825 measure: Frequency and severity of treatment emergent adverse events (TEAEs) of BBI-825 measure: Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of BBI-825 measure: Maximum observed plasma concentration (Cmax) of BBI-825 measure: Trough observed plasma concentration (Ctrough) of BBI-825 measure: Time to Cmax (Tmax) of BBI-825 measure: Area under the concentration time curve (AUC) of BBI-825 measure: Anti-tumor activity of BBI-825 as determined by RECISTv1.1 sex: ALL minimumAge: 18 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sarcoma Oncology Research Center status: RECRUITING city: Santa Monica state: California zip: 90403 country: United States lat: 34.01945 lon: -118.49119 facility: START Midwest status: RECRUITING city: Grand Rapids state: Michigan zip: 49546 country: United States lat: 42.96336 lon: -85.66809 facility: NEXT Oncology status: RECRUITING city: San Antonio state: Texas zip: 78229 country: United States lat: 29.42412 lon: -98.49363 hasResults: False
nctId: NCT06299748 id: ARGX-113-PAC-2206 briefTitle: A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding. overallStatus: NOT_YET_RECRUITING date: 2024-02-29 date: 2033-12 date: 2033-12 date: 2024-03-08 date: 2024-03-08 name: argenx class: INDUSTRY briefSummary: This is a multi-country, prospective safety study of pregnant women exposed to efgartigimod any time within 25 days prior to conception or any time during pregnancy. Women exposed to efgartigimod only during breastfeeding will also be eligible to enroll. Background rates of major congenital malformations (MCMs) will be obtained from populations within the same countries/regions as the countries/regions in which the VYVGART IV or SC-exposed pregnancies were reported. conditions: Myasthenia Gravis studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: OTHER count: 279 type: ESTIMATED name: Efgartigimod measure: Pregnancy outcomes measure: Congenital malformations measure: The number of observed other events of interest in the developing neonate and infant (such as hospitalizations for serious illness) measure: Maternal complications of pregnancy measure: Maternal infections measure: The number of observed fetal growth deficiency sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06299735 id: AsenaIremYildiz1 briefTitle: Comparison of Airway Management With Bronchial Blocker and Double-Lumen Tube in Single-Lung Ventilation overallStatus: RECRUITING date: 2024-02-01 date: 2024-08-31 date: 2024-09-30 date: 2024-03-08 date: 2024-04-17 name: Ankara City Hospital Bilkent class: OTHER briefSummary: In this study, the primary aim is to compare the impact of using a double-lumen tube and bronchial blocker for single-lung ventilation in patients undergoing minimal invasive cardiac surgeries on postoperative pulmonary functions. Secondary objectives include the comparison of application duration, success in lung collapse, and the number of repositioning attempts for both techniques. conditions: Heart Valvular Disease conditions: Coronary Arteriosclerosis conditions: One-lung Ventilation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The anesthesia method applied for both patient groups is the same. However, the airway maintenance device used will vary between two different patient groups. Group BB: A bronchial blocker will be used for this patient group, Group DLT: A double-lumen tube will be used for this patient group. The parameters to be recorded for both patient groups include: preoperative smoking history, ARISCAT score, systolic arterial pressure, diastolic arterial pressure, saturation, pulse, and the duration of airway device insertion following anesthesia induction and intubation. For the assessment of postoperative pulmonary complications in both patient groups, arterial blood gas analysis, chest X-ray, respiratory sounds, and the patient's oxygen requirement will be monitored every 6 hours for 24 hours. primaryPurpose: PREVENTION masking: SINGLE whoMasked: PARTICIPANT count: 66 type: ESTIMATED name: Minimally Invasive Cardiac Surgery (airway management with double-lumen tube) name: Minimally Invasive Cardiac Surgery (airway management with endobronchial blocker) measure: Comparison of Postoperative Pulmonary Complications in Patient Groups Undergoing Single-Lung Ventilation with Double-Lumen Tube and Bronchial Blocker measure: Duration of insertion of the double-lumen tube / bronchial blocker measure: Incidence of postoperative sore throat measure: Incidence of postoperative hoarseness measure: Impact of the success of lung collapse measure: Satisfactory lung collapse time sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ankara bilkent city hospital status: RECRUITING city: Ankara state: Çankaya zip: 06530 country: Turkey lat: 39.91987 lon: 32.85427 hasResults: False
nctId: NCT06299709 id: VX23-121-012 briefTitle: A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA) overallStatus: RECRUITING date: 2024-03-13 date: 2024-06 date: 2024-06 date: 2024-03-08 date: 2024-04-01 name: Vertex Pharmaceuticals Incorporated class: INDUSTRY briefSummary: The purpose of this study is to evaluate the relative bioavailability, food effect, and dose proportionality of a granule formulation of VNZ/TEZ/D-IVA. conditions: Cystic Fibrosis studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: NONE count: 34 type: ESTIMATED name: VNZ/TEZ/D-IVA name: VNZ/TEZ/D-IVA measure: Part A: Maximum Observed Plasma Concentration (Cmax) of VNZ, TEZ, and D-IVA measure: Part B: Maximum Observed Plasma Concentration (Cmax) of VNZ, TEZ, and D-IVA measure: Part A: Area Under the Concentration Versus Time Curve (AUC) of VNZ, TEZ, and D-IVA measure: Part B: Area Under the Concentration Versus Time Curve (AUC) of VNZ, TEZ, and D-IVA measure: Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) measure: Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: Celerion, Inc. status: RECRUITING city: Tempe state: Arizona zip: 85283 country: United States lat: 33.41477 lon: -111.90931 hasResults: False
nctId: NCT06299696 id: VX23-121-011 briefTitle: A Study of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) in Healthy Adult Panelists overallStatus: ENROLLING_BY_INVITATION date: 2024-03-26 date: 2024-05 date: 2024-05 date: 2024-03-08 date: 2024-04-08 name: Vertex Pharmaceuticals Incorporated class: INDUSTRY briefSummary: The purpose of this study is to evaluate the flavor (basic tastes, aroma, texture, mouthfeel) of VNZ/TEZ/D-IVA fixed dose combination (FDC) granules. conditions: Cystic Fibrosis studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: BASIC_SCIENCE masking: NONE count: 10 type: ESTIMATED name: VNZ/TEZ/D-IVA measure: Flavor Assessment Based on Flavor Profile Method of Descriptive Sensory Analysis per American Society for Testing and Material (ASTM) Approved Sensory Evaluation Method sex: ALL minimumAge: 25 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Site 001 city: Woburn state: Massachusetts zip: 01801 country: United States lat: 42.47926 lon: -71.15228 hasResults: False
nctId: NCT06299683 id: 230487 id: 1R01DK133415-01A1 type: NIH link: https://reporter.nih.gov/quickSearch/1R01DK133415-01A1 briefTitle: Pain Type and Interstitial Cystitis/Bladder Pain Syndrome Treatment overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2027-04-05 date: 2028-08-04 date: 2024-03-08 date: 2024-03-08 name: Vanderbilt University Medical Center class: OTHER name: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) briefSummary: Interstitial cystitis/bladder pain syndrome (IC/BPS) is a severe pain condition affecting 3-8 million people in the United States lacking treatments that work. Emotional suffering is common in IC/BPS and known to make physical symptoms worse, and studies show patient sub-groups respond differently to treatment. Individuals with IC/BPS have distinct subgroups, or "phenotypes," largely characterized by the distribution of pain throughout the body. Supported by our preliminary evidence, the overall goal of this project is to assess how IC/BPS phenotype may affect response to two different therapies often given without regard to patient phenotype, pelvic floor physical therapy (PT) and cognitive-behavioral therapy (CBT) for IC/BPS. conditions: Chronic Interstitial Cystitis conditions: Bladder Pain Syndrome conditions: Painful Bladder Syndrome conditions: Cystitis, Interstitial conditions: Cystitis, Chronic Interstitial conditions: Interstitial Cystitis conditions: Interstitial Cystitis, Chronic conditions: Interstitial Cystitis (Chronic) With Hematuria conditions: Interstitial Cystitis (Chronic) Without Hematuria conditions: Chronic Prostatitis conditions: Chronic Prostatitis With Chronic Pelvic Pain Syndrome studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The study involves a two group parallel design, with one group receiving individual psychosocial intervention online and another pelvic floor physical therapy. primaryPurpose: TREATMENT masking: NONE maskingDescription: Study assessors will be blinded to the study primary outcome but will be aware of study treatment conditions. count: 220 type: ESTIMATED name: Psychosocial Treatment name: Pelvic Floor Physical Therapy measure: Differences in response to treatment by phenotype measured by the Global Response Assessment (GRA) scale. measure: Chronic Overlapping Pain Condition-Screener (COPCS) measure: Quantitative Sensory Testing - Tolerance Average (QST-TOL) measure: Quantitative Sensory Testing - Threshold Average (QST-THR) measure: Quantitative Sensory Testing - Temporal Summation (QST-TS) measure: Urinary Nerve Growth Factor (NGF) measure: Urinary Interleukin-6 (IL6) measure: Interleukin-6, whole blood stimulated (IL6-LPS) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06299670 id: 939 briefTitle: Efficacy of Combination of Hdroxyurea and Thalidomide Over Either Hydroxyurea or Thalidomide Alone in the Treatment of Transfusion Dependent Thalassemia in Children: A Quasi-Randomised Clinical Trial overallStatus: RECRUITING date: 2023-11-01 date: 2024-06-30 date: 2024-12-31 date: 2024-03-08 date: 2024-03-08 name: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh class: OTHER briefSummary: Transfusion Dependent Thalassemia (TDT) is an emerging global public health concern. Hemopoietic stem cell transplantation (HSCT) is the only curative treatment. But its adoption is limited due to lack of HLA matched donor, experienced centers and high initial cost. So, researches are going on in search of an effective, safe, easily available treatment option. Use of fetal haemoglobin inducing agents shows promising effects in treatment of TDT patients. Thalidomide an immunomodulating and anti-angiogenic drug has been shown to induce γ-globin gene expression and increase the proliferation of erythroid cells. Furthermore Hydroxyurea (HU) is known to increase haemoglobin (Hb) by HbF induction and reduction of inflammation and hypercoagulability.
This single centered non blinded quasi randomized clinical trial will be conducted at the Department of Pediatric Hematology and Oncology in Bangabandhu Sheikh Mujib Medical University (BSMMU), Bangladesh for one year of period. Thirty transfusion dependent thalassemia children of 3-18 years old will be included in each group. The objective of this study is to assess the effectiveness of combination of Thalidomide and Hydroxyurea in TDT children. It will play an important role in planning a cost effective and affordable treatment option for TDT children.This study will involve minimum physical risk to the patient. Written informed consent will be taken from parents or study subjects after brief explanation of the purpose and procedure. They will also be informed about the freedom to participate or not to participate at any time. Privacy and confidentiality will be safe guarded. History regarding age, sex, height, weight of these patients will be taken. Thorough physical examinations and laboratory investigations including CBC, Hb electrophoresis, serum Ferritin, serum creatinine, SGPT will be done. Data will be collected in a predesigned questionnaire and will be kept confidential. Statistical analysis will be done using the statistical software SPSS. conditions: Transfusion-dependent Thalassemia studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 90 type: ESTIMATED name: Thalidomide name: Hydroxy Urea name: Combinations measure: Change in Hb Level measure: Change in Blood transfusion frequency measure: Change in HbF measure: Change in Biochemicals measure: Adverse effect sex: ALL minimumAge: 3 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: Bangabandhu Sheikh Mujib Medical University status: RECRUITING city: Dhaka zip: 1000 country: Bangladesh name: Md. Anwarul Karim, MBBS, FCPS, MD role: CONTACT phone: +880255165814 email: drkarim1990@gmail.com lat: 23.7104 lon: 90.40744 hasResults: False
nctId: NCT06299657 id: 2023H0286 briefTitle: Intervention for Managing Physical Reactions to Overwhelming Emotions acronym: IMPROVE overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2026-03 date: 2026-03 date: 2024-03-08 date: 2024-03-08 name: Ohio State University class: OTHER briefSummary: The clinical trial aims to conduct a feasibility, acceptability, and usability clinical trial of a modular CBT-based and technologically enhanced intervention for people with an SUD and recently enrolled in IOP, probe target engagement and change in clinical outcomes, and examine attrition rates in IOP.